These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8975096)

  • 1. [Lanreotide++: a new therapeutic option in acromegaly].
    Díez JJ
    Med Clin (Barc); 1996 Sep; 107(7):257-69. PubMed ID: 8975096
    [No Abstract]   [Full Text] [Related]  

  • 2. Lanreotide Autogel: a review of its use in the management of acromegaly.
    Croxtall JD; Scott LJ
    Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of lanreotide.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1301-12. PubMed ID: 20716034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanreotide autogel in acromegaly - a decade on.
    Kyriakakis N; Chau V; Lynch J; Orme SM; Murray RD
    Expert Opin Pharmacother; 2014 Dec; 15(18):2681-92. PubMed ID: 25307803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs: Maraviroc and Lanreotide.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(6):778-83. PubMed ID: 18032144
    [No Abstract]   [Full Text] [Related]  

  • 6. Somatostatin analogs in acromegaly.
    Freda PU
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid.
    Krassowski J; Zgliczyński W; Jeske W; Zgliczyński S
    J Clin Endocrinol Metab; 1999 May; 84(5):1761-2. PubMed ID: 10323416
    [No Abstract]   [Full Text] [Related]  

  • 8. Depot somatostatin analogs--a new first line therapy for acromegaly.
    Robbins RJ
    J Clin Endocrinol Metab; 1997 Jan; 82(1):15-7. PubMed ID: 8989224
    [No Abstract]   [Full Text] [Related]  

  • 9. Somatuline LA: a new treatment for acromegaly.
    Bouloux PM
    Hosp Med; 1998 Aug; 59(8):642-5. PubMed ID: 9829060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacological aspects of the treatment of acromegaly.
    Giustina A; Zaltieri G; Negrini F; Wehrenberg WB
    Pharmacol Res; 1996; 34(5-6):247-68. PubMed ID: 9076850
    [No Abstract]   [Full Text] [Related]  

  • 11. [Complete regression of a somatotropin-secreting adenoma with lanreotide monotherapy].
    Ilias I; Mastorakos G
    Presse Med; 2000 Nov; 29(33):1818-9. PubMed ID: 11109436
    [No Abstract]   [Full Text] [Related]  

  • 12. Lanreotide Autogel in the management of acromegaly.
    Molitch ME
    Drugs; 2008; 68(5):724. PubMed ID: 18370451
    [No Abstract]   [Full Text] [Related]  

  • 13. Incomplete analgesic effect of lanreotide in acromegaly.
    Maffei P; Martini C; Sicolo N
    Headache; 1997 May; 37(5):299-300. PubMed ID: 9195771
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of acromegaly with a new slow release somatostatin analog, lanreotide].
    Boucekkine C; Catus F; Blumberg-Tick J; Pholséna M; Chanson P; Schaison G
    Ann Endocrinol (Paris); 1994; 55(6):261-9. PubMed ID: 7864583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):13-5. PubMed ID: 27168107
    [No Abstract]   [Full Text] [Related]  

  • 16. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly.
    Hua SC; Yan YH; Chang TC
    Eur J Endocrinol; 2006 Dec; 155(6):831-7. PubMed ID: 17132752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid.
    Drange MR; Melmed S
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3104-9. PubMed ID: 9745411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pregnancy in an acromegalic patient treated with lanreotide and bromocryptin].
    Sánchez R; Boix E; del Pino Navarro M; Picó A
    Med Clin (Barc); 1999 Jul; 113(5):198. PubMed ID: 10480146
    [No Abstract]   [Full Text] [Related]  

  • 19. Uneventful pregnancy in an acromegalic patient treated with slow-release lanreotide: a case report.
    de Menis E; Billeci D; Marton E; Gussoni G
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1489. PubMed ID: 10199803
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of delayed-release lanreotide in the medical therapy of acromegaly].
    Papi G; Magnoni I; Pesenti M; Gola M; Tavernari V; Velardo A
    Minerva Endocrinol; 1998 Jun; 23(2):57-63. PubMed ID: 9844356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.